The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Avastin, an angiogenesis inhibitor, is currently approved for treatment of 2 different forms of advanced cancer that recurred after platinum-based chemotherapy (non-squamous non—small cell lung cancer, carcinoma of the colon or rectum, and renal cell carcinoma). The FDA is expected to decide on whether to approve the new indication for Avastin by June 25, 2018.
This sBLA for Avastin, in the combination and order of treatment as specified, is based on data from the pivotal phase 3 GOG-0218 trial, which was conducted by the Gynecologic Oncology Group and published in The New England Journal of Medicine. GOG-0218 was a multicenter, randomized, double-blind, placebo-controlled phase 3 study in 1873 women with previously untreated advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who already had surgery to remove as much of the tumor as possible. Study participants were randomized to 1 of 3 treatment arms:
Women who received Avastin in combination with chemotherapy, and continued use of Avastin alone for a duration of 22 cycles, lived the longest without disease progression, with a median progression-free survival of 18.2 months compared with 12.0 months in women who received chemotherapy alone (hazard ratio, 0.64; 95% confidence interval, 0.54-0.77; P < .001).
Secondary endpoints of the study included overall survival and objective response rate. Adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications, the company said.
The sBLA seeking the new indication follows closely on the heels of the FDA’s approval of Amgen’s bevacizumab biosimilar, ABP 215 (Mvasi), the first biosimilar of Avastin approved for use in the United States. Amgen, seeking to launch its product, is currently engaged in a lawsuit against Genentech in a California district court. Amgen seeks a judgment that its biosimilar has not infringed on 27 patents covering the reference bevacizumab. When Amgen eventually brings Mvasi to the US marketplace, the biosimilar will compete for a share of substantial bevacizumab sales; Avastin was responsible for $6.75 billion in global sales for Genentech in 2016.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.